Fig. 7: Myelotoxicity of CART84 cells in vivo. | Leukemia

Fig. 7: Myelotoxicity of CART84 cells in vivo.

From: A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

Fig. 7

A Experimental design of the humanized NSG mouse model (n = 5–6 mice per group). B–F Percentage of different human subsets in the bone marrow (gated from the human CD45+ population) at day 67 of the experiment. B Percentage of CD45+ human cells gated from the entire bone marrow. C Percentage of human T lymphocytes (hCD3+). D Percentage of human B lymphocytes (hCD19+). E Percentage of human HSPC (hCD34+). F Percentage of human myeloid cells (hCD33+) G Human cell populations per mouse group. Statistical analysis of bone marrow cell populations was performed using a one-way ANOVA with multiple comparisons (all vs. all). UT: untransduced T cells. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.

Back to article page